Analysts expect DexCom, Inc. (NASDAQ:DXCM) to post ($0.17) earnings per share for the current fiscal quarter, according to Zacks. Ten analysts have issued estimates for DexCom’s earnings, with the highest EPS estimate coming in at $0.18 and the lowest estimate coming in at ($0.60). DexCom posted earnings of ($0.32) per share during the same quarter last year, which suggests a positive year over year growth rate of 46.9%. The business is scheduled to issue its next quarterly earnings results after the market closes on Wednesday, May 1st.

On average, analysts expect that DexCom will report full year earnings of $0.46 per share for the current year, with EPS estimates ranging from ($0.16) to $0.79. For the next fiscal year, analysts expect that the business will post earnings of $0.94 per share, with EPS estimates ranging from $0.52 to $1.38. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover DexCom.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 21st. The medical device company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.38. DexCom had a negative net margin of 12.32% and a positive return on equity of 4.98%. The firm had revenue of $338.00 million for the quarter, compared to analyst estimates of $331.60 million. During the same period last year, the firm earned $0.10 earnings per share. The business’s quarterly revenue was up 52.9% compared to the same quarter last year.

Several analysts have recently commented on the stock. Morgan Stanley increased their target price on shares of DexCom from $135.00 to $160.00 and gave the company an “equal weight” rating in a report on Monday, February 25th. Piper Jaffray Companies raised their price objective on shares of DexCom to $165.00 and gave the stock an “overweight” rating in a report on Wednesday, January 9th. UBS Group raised their price objective on shares of DexCom from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, January 8th. Cowen raised their price objective on shares of DexCom from $150.00 to $175.00 and gave the stock an “outperform” rating in a report on Friday, February 22nd. Finally, Canaccord Genuity raised their price objective on shares of DexCom from $140.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, February 22nd. Six analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $149.53.

In related news, CEO Kevin R. Sayer sold 32,566 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $142.83, for a total transaction of $4,651,401.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark G. Foletta sold 1,000 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $118.98, for a total transaction of $118,980.00. Following the sale, the director now owns 4,052 shares of the company’s stock, valued at approximately $482,106.96. The disclosure for this sale can be found here. Insiders have sold 96,048 shares of company stock valued at $13,514,383 in the last 90 days. 1.80% of the stock is currently owned by corporate insiders.

A number of large investors have recently modified their holdings of DXCM. Dimensional Fund Advisors LP boosted its position in DexCom by 1.1% during the third quarter. Dimensional Fund Advisors LP now owns 161,295 shares of the medical device company’s stock worth $23,073,000 after purchasing an additional 1,758 shares during the period. Paloma Partners Management Co bought a new position in shares of DexCom in the third quarter valued at approximately $429,000. Man Group plc boosted its position in shares of DexCom by 39.1% in the third quarter. Man Group plc now owns 93,409 shares of the medical device company’s stock valued at $13,361,000 after acquiring an additional 26,269 shares during the period. HPM Partners LLC bought a new position in shares of DexCom in the third quarter valued at approximately $203,000. Finally, HRT Financial LLC bought a new position in shares of DexCom in the third quarter valued at approximately $320,000. Hedge funds and other institutional investors own 97.96% of the company’s stock.

DexCom stock opened at $114.29 on Friday. DexCom has a 1-year low of $72.04 and a 1-year high of $156.16. The firm has a market capitalization of $10.29 billion, a price-to-earnings ratio of 380.97 and a beta of 0.75. The company has a debt-to-equity ratio of 1.52, a quick ratio of 7.32 and a current ratio of 7.64.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Article: Analyst Ratings Trading

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.